Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases.
Excellent balance sheet with limited growth.
Share Price & News
How has Spark Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ONCE has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ONCE exceeded the US Biotechs industry which returned 10.9% over the past year.
Return vs Market: ONCE exceeded the US Market which returned 24.7% over the past year.
Price Volatility Vs. Market
How volatile is Spark Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StDoes Spark Therapeutics, Inc.'s (NASDAQ:ONCE) CEO Pay Reflect Performance?
1 year ago | Simply Wall StWhat You Must Know About Spark Therapeutics Inc's (NASDAQ:ONCE) Financial Health
1 year ago | Simply Wall StAnalysts Expect Breakeven For Spark Therapeutics Inc (NASDAQ:ONCE)
Is Spark Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ONCE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ONCE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ONCE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ONCE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ONCE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ONCE is overvalued based on its PB Ratio (12.7x) compared to the US Biotechs industry average (3.2x).
How is Spark Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ONCE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ONCE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ONCE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ONCE's revenue (33.9% per year) is forecast to grow faster than the US market (7.5% per year).
High Growth Revenue: ONCE's revenue (33.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ONCE is forecast to be unprofitable in 3 years.
How has Spark Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ONCE is currently unprofitable.
Growing Profit Margin: ONCE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ONCE is unprofitable, and losses have increased over the past 5 years at a rate of -27% per year.
Accelerating Growth: Unable to compare ONCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONCE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).
Return on Equity
High ROE: ONCE has a negative Return on Equity (-72.38%), as it is currently unprofitable.
How is Spark Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ONCE's short term assets ($467.9M) exceed its short term liabilities ($100.3M).
Long Term Liabilities: ONCE's short term assets ($467.9M) exceed its long term liabilities ($257.2M).
Debt to Equity History and Analysis
Debt Level: ONCE's debt to equity ratio (14.2%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ONCE's debt to equity ratio has reduced over the past 5 years.
Inventory Level: ONCE has a high level of physical assets or inventory.
Debt Coverage by Assets: ONCE's debt is covered by short term assets (assets are 9.5x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ONCE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ONCE has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 3.7% each year.
What is Spark Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ONCE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ONCE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ONCE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ONCE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ONCE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jeff Marrazzo (40yo)
Mr. Jeffrey D. Marrazzo, also known as Jeff, M.B.A., M.P.A. is a Co-Founder of Spark Therapeutics, Inc. (a/k/a, Spark Therapeutics, LLC) and has been its Chief Executive Officer since May 2013. Mr. Marrazz ...
CEO Compensation Analysis
Compensation vs Market: Jeff's total compensation ($USD3.60M) is about average for companies of similar size in the US market ($USD4.99M).
Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||5.42yrs||US$2.05m||0.016% $698.6k|
|Chief Business Officer||3.58yrs||US$2.55m||0.10% $4.4m|
|Scientific Co-Founder||no data||no data||no data|
|Scientific Co-Founder and Advisor||no data||no data||no data|
|Scientific Co-Founder and Advisor||no data||no data||no data|
|Chief Scientific Officer||2.25yrs||no data||0.033% $1.4m|
|Head of Investor Relations||no data||no data||no data|
|Chief Legal Officer & Secretary||5.92yrs||US$2.00m||0.13% $5.8m|
Experienced Management: ONCE's management team is seasoned and experienced (5.3 years average tenure).
|Independent Director||5.5yrs||US$387.89k||0.0078% $343.6k|
|Independent Director||3.92yrs||US$399.47k||0.0078% $343.6k|
|Independent Director||5.58yrs||US$397.89k||0.0078% $343.6k|
|Independent Director||5.92yrs||US$388.20k||0.037% $1.6m|
|Independent Director||1.92yrs||US$845.74k||0.0065% $286.2k|
|Independent Director||5.58yrs||US$379.11k||no data|
Experienced Board: ONCE's board of directors are considered experienced (5.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.
Spark Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Spark Therapeutics, Inc.
- Ticker: ONCE
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.410b
- Shares outstanding: 38.52m
- Website: https://www.sparktx.com
Number of Employees
- Spark Therapeutics, Inc.
- 3737 Market Street
- Suite 1300
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ONCE||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jan 2015|
|272||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 2015|
|0L8L||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 2015|
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company’s gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company’s preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/12/19 00:40|
|End of Day Share Price||2019/12/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.